France creates 10m-euro compensation fund for epilepsy drug victims


More than 14,000 women in France were prescribed Depakine, the Sanofi drug firm's brand name for valproate, despite the potential risks to foetuses which became known in the early 1980s, and which associations representing victims say may have affected  50,000 people in the country.

Reading articles is for subscribers only. Subscribe now.

France is setting up a fund to meet compensation claims from people affected by an epilepsy treatment made by Sanofi that is believed to cause birth malfunctions and slow neurological development, reports Reuters.